Jeremiah Bearss
Vice President of Clinical Development Biolexis Therapeutics
Seminars
Thursday 29th January 2026
Redefining Obesity & Aging: Combining Oral GLP-1 and Isoform- Selective AMPK Activation to Preserve Muscle & Metabolic Health
9:00 am
- Aging and Muscle Loss as a Critical Challenge: Sarcopenia and age-related muscle dysfunction are major drivers of frailty, metabolic decline, and loss of independence in older adults
- Targeting Muscle Biology with BLX-0871: Biolexis’ isoform-selective AMPK activator, BLX-0871, uniquely stimulates glucose uptake and boosts muscle metabolism, counteracting muscle wasting and metabolic deterioration during aging
- Expanding the Role of GLP-1 with BLX-7006: Our novel oral GLP-1 receptor agonist, BLX-7006, provides weight loss and metabolic benefits while avoiding injection-related barriers to patient adoption.
- A New Paradigm for Healthy Aging: The combination of BLX-0871 and BLX-7006 offers a synergistic approach: driving weight loss, preserving lean muscle mass, and addressing age-related diseases by restoring metabolic resilience
